Sujani Poonuru, MD
Endocrinology, Diabetes & Metabolism · Marshfield, WINPI 1821246406
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Lilly USA, LLC at 30.3% of the total. Reporting peaked in 2021 at $289 and has fallen 86.9% since, to $38 in 2025.
Across 34 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$198
- Abbott$156
- Amgen$50
- Radius Health, Inc.$48
- Novo Nordisk$46
- Cequr Corporation$44
- plus $111 from 6 others
What the payments were for
- Food & beverage$653100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $198 |
| Abbott | 8 | $156 |
| Amgen | 1 | $50 |
| Radius Health, Inc. | 2 | $48 |
| Novo Nordisk | 3 | $46 |
| Cequr Corporation | 2 | $44 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Insulet Corporation | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Bayer | 1 | $15 |
How this compares
$653 in reported general payments places this provider in the 60th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 285 | $442,306 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 121 | $201,653 |
| MounjaroTirzepatide | 103 | $141,475 |
| JardianceEmpagliflozin | 121 | $120,381 |
| TrulicityDulaglutide | 87 | $112,548 |
| Tresiba Flextouch U-100Insulin Degludec | 105 | $61,616 |
| FarxigaDapagliflozin Propanediol | 64 | $61,605 |
| ProliaDenosumab | 30 | $53,723 |
| Humulin R U-500Insulin Regular, Human | 28 | $47,913 |
| RybelsusSemaglutide | 23 | $33,060 |
| TradjentaLinagliptin | 43 | $31,648 |
| Cinacalcet Hcl | 64 | $22,811 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 26 | $22,707 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $19,574 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 19 | $14,272 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $46 | $488,136345 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $198 | $262,411229 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $18 | $174,735190 claims |
| AmgenProlia | $50 | $53,72330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Marshfield
- Aron AdkinsEau Claire$349K
- Steven RabinoweRacine$344K
- Daniel Shortla Crosse$328K
- Laura AndrewsMenasha$294K
- Amy DeguemeMequon$143K
- James FindlingMenomonee Falls$78K
- Neil BinkleyMadison$76K
- Vinay PatelNeenah$64K
- Denise Teves QuallerMilwaukee$56K
- Elaine DrobnyMilwaukee$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.